×
About 2,057 results

ALLMedicine™ Hypogammaglobulinemia Center

Research & Reviews  1,007 results

Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-bas...
https://doi.org/10.1093/ajhp/zxab072
American Journal of Health-system Pharmacy : AJHP : Offic... Perreault S, Schiffer M et. al.

Feb 22nd, 2021 - In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted onlin...

COVID-19, HHV6 and MOG antibody: A perfect storm.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879032
Journal of Neuroimmunology; Jumah M, Rahman F et. al.

Feb 19th, 2021 - Serious neurological complications of SARS-CoV-2 are increasingly being recognized. We report a novel case of HHV6 myelitis with parainfectious MOG-IgG in the setting of COVID-19-induced lymphopenia and hypogammaglobulinemia. The patient experienc...

Evaluation of the protein gap for detection of abnormal serum gammaglobulin level: an i...
https://doi.org/10.1515/cclm-2020-1286
Clinical Chemistry and Laboratory Medicine; Suleman A, Cameron DW et. al.

Feb 8th, 2021 - The value of the serum protein gap (PG, difference between total protein and albumin) in the detection of hyper- or hypogammaglobulinemia is not well established. We assessed the performance of PG for the detection of hyper- or hypogammaglobulinem...

A clinician survey for management of the secondary immunodeficiency caused by hematolog...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837821
Medicine Ye C, Liu J et. al.

Feb 6th, 2021 - Unlike Western countries, there are still few clinical immunology specialists in China, and the optimal care for secondary immunodeficiency caused by hematological malignancies is unknown. Therefore, we initiated this clinician survey study to des...

Immunoglobulin therapy for successful management of prolonged, recurrent jaundice in a ...
https://doi.org/10.1007/s12328-021-01347-0 10.1002/hep.28967 10.1111/imj.12609 10.3748/wjg.v23.i2.366 10.1155/2013/484903 10.3748/wjg.v19.i1.115
Clinical Journal of Gastroenterology; Oda C, Tsuchiya A et. al.

Feb 2nd, 2021 - Jaundice may be persistent in drug-induced liver injury associated with vanishing bile duct syndrome. However, recurrent jaundice is atypical, following bile flow restoration. Here, we report a 28-year-old man with prolonged, recurrent jaundice (m...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  1,025 results

Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-bas...
https://doi.org/10.1093/ajhp/zxab072
American Journal of Health-system Pharmacy : AJHP : Offic... Perreault S, Schiffer M et. al.

Feb 22nd, 2021 - In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted onlin...

COVID-19, HHV6 and MOG antibody: A perfect storm.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879032
Journal of Neuroimmunology; Jumah M, Rahman F et. al.

Feb 19th, 2021 - Serious neurological complications of SARS-CoV-2 are increasingly being recognized. We report a novel case of HHV6 myelitis with parainfectious MOG-IgG in the setting of COVID-19-induced lymphopenia and hypogammaglobulinemia. The patient experienc...

Evaluation of the protein gap for detection of abnormal serum gammaglobulin level: an i...
https://doi.org/10.1515/cclm-2020-1286
Clinical Chemistry and Laboratory Medicine; Suleman A, Cameron DW et. al.

Feb 8th, 2021 - The value of the serum protein gap (PG, difference between total protein and albumin) in the detection of hyper- or hypogammaglobulinemia is not well established. We assessed the performance of PG for the detection of hyper- or hypogammaglobulinem...

A clinician survey for management of the secondary immunodeficiency caused by hematolog...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837821
Medicine Ye C, Liu J et. al.

Feb 6th, 2021 - Unlike Western countries, there are still few clinical immunology specialists in China, and the optimal care for secondary immunodeficiency caused by hematological malignancies is unknown. Therefore, we initiated this clinician survey study to des...

Immunoglobulin therapy for successful management of prolonged, recurrent jaundice in a ...
https://doi.org/10.1007/s12328-021-01347-0 10.1002/hep.28967 10.1111/imj.12609 10.3748/wjg.v23.i2.366 10.1155/2013/484903 10.3748/wjg.v19.i1.115
Clinical Journal of Gastroenterology; Oda C, Tsuchiya A et. al.

Feb 2nd, 2021 - Jaundice may be persistent in drug-induced liver injury associated with vanishing bile duct syndrome. However, recurrent jaundice is atypical, following bile flow restoration. Here, we report a 28-year-old man with prolonged, recurrent jaundice (m...

see more →

News  21 results

Novel Study Explores Link Between Primary Immunodeficiencies, Rheumatic Diseases
https://www.staging.medscape.com/viewarticle/939605

Oct 21st, 2020 - Fully 48% of patients with autoimmune rheumatic diseases who developed persistent hypogammaglobulinemia after initiating treatment with immunomodulatory agents harbored gene variants associated with inborn errors of immunity, according to the find...

Novel Study Explores Link Between Primary Immunodeficiencies, Rheumatic Diseases
https://www.medscape.com/viewarticle/939605

Oct 21st, 2020 - Fully 48% of patients with autoimmune rheumatic diseases who developed persistent hypogammaglobulinemia after initiating treatment with immunomodulatory agents harbored gene variants associated with inborn errors of immunity, according to the find...

Hypogammaglobulinemia and infection risk clarified in MS patients on anti-CD20 agents
https://www.mdedge.com/multiplesclerosishub/article/209320/multiple-sclerosis/hypogammaglobulinemia-and-infection-risk/page/0/1

Oct 2nd, 2019 - Ocrelizumab Tobias Derfuss, MD, provided data on infection rates in the pivotal phase 3 OPERA and ORATIO double-blind clinical trials combined with their long-term, open-label extensions totaling 288 weeks, or nearly 6 years, of follow-up. Serum I.

Plerixafor produced dramatic responses in severe WHIM syndrome
https://www.mdedge.com/familymedicine/article/192393/anemia/plerixafor-produced-dramatic-responses-severe-whim-syndrome
MDedge Hematology and Oncology; Amy Karon

Jan 9th, 2019 - Low-dose treatment with plerixafor, a CXC chemokine receptor 4 antagonist, was well tolerated and markedly improved severe presentations of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome in three patients who could not.

Long-term side effects of CAR T cells mostly mild
https://www.mdedge.com/hematology-oncology/article/192072/cellular-therapy/long-term-side-effects-car-t-cells-mostly-mild
Neil Osterweil

Jan 4th, 2019 - SAN DIEGO – Longer-term follow-up of patients treated with CD19-targeted chimeric antigen receptor (CAR) T cells for hematologic malignancies indicates that the altered cells are generally safe, with most late events being mild in nature and possi.

see more →